Loading
PDBj
メニューPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

5FBI

COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 3b

5FBI の概要
エントリーDOI10.2210/pdb5fbi/pdb
分子名称Complement factor D, GLYCEROL, 3-[(2-aminocarbonyl-1~{H}-indol-5-yl)oxymethyl]benzoic acid, ... (4 entities in total)
機能のキーワードhydrolase
由来する生物種Homo sapiens (Human)
細胞内の位置Secreted: P00746
タンパク質・核酸の鎖数1
化学式量合計25141.52
構造登録者
Ostermann, N.,Zink, F. (登録日: 2015-12-14, 公開日: 2016-10-26, 最終更新日: 2024-10-09)
主引用文献Maibaum, J.,Liao, S.M.,Vulpetti, A.,Ostermann, N.,Randl, S.,Rudisser, S.,Lorthiois, E.,Erbel, P.,Kinzel, B.,Kolb, F.A.,Barbieri, S.,Wagner, J.,Durand, C.,Fettis, K.,Dussauge, S.,Hughes, N.,Delgado, O.,Hommel, U.,Gould, T.,Mac Sweeney, A.,Gerhartz, B.,Cumin, F.,Flohr, S.,Schubart, A.,Jaffee, B.,Harrison, R.,Risitano, A.M.,Eder, J.,Anderson, K.
Small-molecule factor D inhibitors targeting the alternative complement pathway.
Nat.Chem.Biol., 12:1105-1110, 2016
Cited by
PubMed Abstract: Complement is a key component of the innate immune system, recognizing pathogens and promoting their elimination. Complement component 3 (C3) is the central component of the system. Activation of C3 can be initiated by three distinct routes-the classical, the lectin and the alternative pathways-with the alternative pathway also acting as an amplification loop for the other two pathways. The protease factor D (FD) is essential for this amplification process, which, when dysregulated, predisposes individuals to diverse disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH). Here we describe the identification of potent and selective small-molecule inhibitors of FD. These inhibitors efficiently block alternative pathway (AP) activation and prevent both C3 deposition onto, and lysis of, PNH erythrocytes. Their oral administration inhibited lipopolysaccharide-induced AP activation in FD-humanized mice. These data demonstrate the feasibility of inhibiting the AP with small-molecule antagonists and support the development of FD inhibitors for the treatment of complement-mediated diseases.
PubMed: 27775713
DOI: 10.1038/nchembio.2208
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.47 Å)
構造検証レポート
Validation report summary of 5fbi
検証レポート(詳細版)ダウンロードをダウンロード

226707

件を2024-10-30に公開中

PDB statisticsPDBj update infoContact PDBjnumon